Citius Oncology, Inc. CTOR
0.50 USD -0.05 (-8.57%)
At closeNov 6, 2026, 4:26 AM EST
0.54 +0.04 +8.18%
Pre-market · Nov 6, 4:26 AM ET
0.4936 Day range 0.5774
0.491 52-week range 1.83
- YTD
- -49.99%
- 1 year
- -65.27%
- Market cap
- 52.89M
- EPS (ttm)
- -0.48
- Shares out
- 71.30M
- YTD return
- -49.99%
- 1-year return
- -65.27%
- Volume
- 145.28K
- Avg volume
- 111.29K
- Open
- 0.5481
- Previous close
- 0.547
- Day's range
- 0.4936 – 0.5774
- 52-week range
- 0.491 – 1.83
- Price target
- 3.00 (+499.9%)
5D -0.0264 (-5.01%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 7.11M
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -85.28%
- Short % of float
- 0.00%
- 50-day average
- 1.13
- 200-day average
- 7.55
Analyst view
Price target (mean) 3.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CTOR Revenue — quarterly 1.49M
CTOR Net income — quarterly -8.92M
CTOR EPS — quarterly -0.08
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | Maxim Group | init | — | Buy |
| Aug 13, 2024 | EF Hutton | main | Buy | Buy |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
News
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe 
12 Health Care Stocks Moving In Monday's After-Market Session 
Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
Your note
Sign in to keep a note on CTOR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Yakira Capital Management, Inc. | 0.66% | 15,499 | 15.19K | Sep 29, 2024 |
| Virtu Financial LLC | 0.44% | 10,291 | 10.09K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.23% | 5,480 | 5.37K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 1,632 | 1.60K | Sep 29, 2024 |
| Bank of America Corporation | 0.01% | 160 | 156 | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.00% | 41 | 40 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.10% | 2,332 | 2.29K | Oct 30, 2024 |